汗腺膿瘍（HS）：上市済み薬剤およびパイプライン薬剤の評価、臨床試験・競合情勢

2022年には、16の医薬品市場において、300万人以上のHSの有病率と診断される見込みです。この適応症には高いアンメットニーズがありますが、後期パイプラインにあるHSの治療法を開発している企業はわずか2社です。

当レポートでは、世界の汗腺膿瘍（HS）治療薬の動向を調査し、疾患・治療の概要、上市済み薬のプロファイル、パイプライン薬および臨床試験の動向、取引情勢、主要企業の動向などをまとめています。

目次

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療概要

第4章 上市済み薬剤の評価

• 主要な上市済み薬剤
• 概要：作用機序別
• 概要：投与経路別
• 上市済み薬剤プロファイルと売上予測

第5章 価格設定と償還の評価

• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

• フェーズIIIのパイプライン薬
• 概要：開発段階別
• 概要：分子タイプ別
• 概要：作用機序別
• 概要：投与経路別
• 薬剤固有のフェーズ移行成功率（PTSR）および承認の可能性（LoA）
• 治療領域および適応症固有のPTSRおよびLoA

第7章 臨床試験の評価

• 概要：実績
• 概要：フェーズ別
• 概要：ステータス別
• 概要：進行中および計画中試験の段階別
• 仮想コンポーネントによるトライアル
• 概要：地域別
• 単一国および多国籍試験：地域別
• 上位20のスポンサーと内訳：フェーズ別
• 上位20のスポンサーと内訳：ステータス別
• 概要：エンドポイントステータス別
• 概要：人種と民族別
• 登録データ
• トライアルサイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析：地理的概要
• 実現可能性分析：ベンチマークモデル

第8章 ディール情勢

• 合併、買収、戦略的提携：地域別
• 最近の合併、買収、および戦略的提携

第9章 商業的評価

• 主要企業

第10章 将来のマーケットカタリスト

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in HS therapeutics.

Synopsis

• In 2022, there will be more than three million diagnosed prevalent cases of HS across 16 pharmaceutical markets.
• T only one FDA-approved medication, Humira (adalimumab), available for the treatment of HS, which is used in severe cases only.
• A total of 57% of drugs in pipeline development for the treatment of HS are biologics.
• Pfizer has sponsored the highest number of clinical trials (14 trials) in HS over the past 10 years.
• During the past 12 months, there have been 11 mergers, acquisitions, and strategic alliances involving companies with HS assets.
• Although there are high unmet needs in this indication, only two companies are developing therapies for HS that are in the late-stage pipeline.

Scope

GlobalData's Hidradenitis Suppurativa (HS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the HS market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HS market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer